Cartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage study-April 2024-www.financetom.com

Cartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage study

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Cartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage study

Jul 2, 2024 3:47 AM

July 2 (Reuters) - Cartesian Therapeutics ( RNAC ) said

on Tuesday that its experimental autoimmune disorder therapy met

the main goal of a mid-stage trial.

Previous page： BRIEF-BKV Corporation Announces Closing Of Initial Public Offering Next page： Prothena Names Chad Swanson as Chief Development Officer; Chief Medical Officer Departs

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

BRIEF-BKV Corporation Announces Closing Of Initial Public Offering

Oct 3, 2024

Sept 27 (Reuters) - BKV Corp ( BKV ): * BKV CORPORATION ANNOUNCES CLOSING OF INITIAL PUBLIC OFFERING * BKV CORP ( BKV ) - CLOSES IPO OF 15 MILLION SHARES AT $18.00 PER SHARE Source text for Eikon: Further company coverage: ...

Prothena Names Chad Swanson as Chief Development Officer; Chief Medical Officer Departs

Oct 3, 2024

04:28 PM EDT, 09/27/2024 (MT Newswires) -- Prothena ( PRTA ) appointed Chad Swanson as chief development officer and said Chief Medical Officer Hideki Garren is leaving to pursue an opportunity at a large pharmaceutical company. Swanson joined as senior vice president and head of clinical development in January 2023, the company said Friday in a statement. Prothena ( PRTA...

US Foods Unit Prices $500 Million Notes Offering

Oct 3, 2024

04:25 PM EDT, 09/27/2024 (MT Newswires) -- US Foods Holding ( USFD ) said Friday its US Foods Inc. unit has priced a private offering of $500 million of 5.75% senior unsecured notes due 2033, with closing expected on Oct. 3. The proceeds will be used to repay a portion of its term loan facility, the company said. Price: 60.16,...

Toll Brothers Insider Sold Shares Worth $7,725,700, According to a Recent SEC Filing

Oct 3, 2024

04:28 PM EDT, 09/27/2024 (MT Newswires) -- Douglas C. Yearley Jr., Director, Chief Executive Officer, on September 27, 2024, sold 50,000 shares in Toll Brothers ( TOL ) for $7,725,700. Following the Form 4 filing with the SEC, Yearley has control over a total of 328,929 shares of the company, with 246,382 shares held directly and 82,547 controlled indirectly. SEC...